Search research articles
Contact Us
Filters
Showing results (281-290 of 345) with videos related to
Page
of 35
Sort By:
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)
|
May 13, 2020
Transdiagnostic clinical staging in youth mental health: a first international consensus statement
Jai L Shah, Jan Scott, Patrick D McGorry, et al.
Current Pharmaceutical Design
|
January 14, 2012
Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study
Gregor E Berger, Stephen J Wood, Margaret Ross, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
April 11, 2006
Optimising antimicrobial prescription in hospitals by introducing an antimicrobial stewardship programme in Hong Kong: consensus statement
P L Ho, J C F Cheng, P T Y Ching, et al.
The British Journal of Psychiatry : the Journal of Mental Science
|
July 3, 2004
Pituitary volume in psychosis
Carmine M Pariante, Konstantina Vassilopoulou, Dennis Velakoulis, et al.
Schizophrenia Bulletin
|
November 23, 2015
The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis
Paolo Fusar-Poli, Frauke Schultze-Lutter, Marco Cappucciati, et al.
The Australian and New Zealand Journal of Psychiatry
|
July 4, 2017
Ventricular volumes across stages of schizophrenia and other psychoses
Gregor E Berger, Cali F Bartholomeusz, Stephen J Wood, et al.
JAMA Psychiatry
|
June 7, 2013
Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study
Barnaby Nelson, Hok Pan Yuen, Stephen J Wood, et al.
Trials
|
November 11, 2017
A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol
Inti Qurashi, Imran B Chaudhry, Ameer B Khoso, et al.
Brain, Behavior, and Immunity
|
November 4, 2023
A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study
Inti Qurashi, Imran B Chaudhry, Ameer B Khoso, et al.
Journal of Affective Disorders
|
March 16, 2025
Activation differentiates illness trajectories among youth seeking mental health care
Emiliana Tonini, Jacob J Crouse, Mirim Shin, et al.
Page
of 35
Search research articles
Search
Showing results (281-290 of 345) with videos related to
Sort By:
Page
of 35
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)
|
May 13, 2020
Transdiagnostic clinical staging in youth mental health: a first international consensus statement
Jai L Shah, Jan Scott, Patrick D McGorry, et al.
Current Pharmaceutical Design
|
January 14, 2012
Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study
Gregor E Berger, Stephen J Wood, Margaret Ross, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
April 11, 2006
Optimising antimicrobial prescription in hospitals by introducing an antimicrobial stewardship programme in Hong Kong: consensus statement
P L Ho, J C F Cheng, P T Y Ching, et al.
The British Journal of Psychiatry : the Journal of Mental Science
|
July 3, 2004
Pituitary volume in psychosis
Carmine M Pariante, Konstantina Vassilopoulou, Dennis Velakoulis, et al.
Schizophrenia Bulletin
|
November 23, 2015
The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis
Paolo Fusar-Poli, Frauke Schultze-Lutter, Marco Cappucciati, et al.
The Australian and New Zealand Journal of Psychiatry
|
July 4, 2017
Ventricular volumes across stages of schizophrenia and other psychoses
Gregor E Berger, Cali F Bartholomeusz, Stephen J Wood, et al.
JAMA Psychiatry
|
June 7, 2013
Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study
Barnaby Nelson, Hok Pan Yuen, Stephen J Wood, et al.
Trials
|
November 11, 2017
A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol
Inti Qurashi, Imran B Chaudhry, Ameer B Khoso, et al.
Brain, Behavior, and Immunity
|
November 4, 2023
A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study
Inti Qurashi, Imran B Chaudhry, Ameer B Khoso, et al.
Journal of Affective Disorders
|
March 16, 2025
Activation differentiates illness trajectories among youth seeking mental health care
Emiliana Tonini, Jacob J Crouse, Mirim Shin, et al.
Page
of 35